JP2004526459A5 - - Google Patents

Download PDF

Info

Publication number
JP2004526459A5
JP2004526459A5 JP2002589661A JP2002589661A JP2004526459A5 JP 2004526459 A5 JP2004526459 A5 JP 2004526459A5 JP 2002589661 A JP2002589661 A JP 2002589661A JP 2002589661 A JP2002589661 A JP 2002589661A JP 2004526459 A5 JP2004526459 A5 JP 2004526459A5
Authority
JP
Japan
Prior art keywords
lymphocytes
antigen
cells
specific
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002589661A
Other languages
English (en)
Japanese (ja)
Other versions
JP4185366B2 (ja
JP2004526459A (ja
Filing date
Publication date
Priority claimed from FR0106231A external-priority patent/FR2824567B1/fr
Application filed filed Critical
Publication of JP2004526459A publication Critical patent/JP2004526459A/ja
Publication of JP2004526459A5 publication Critical patent/JP2004526459A5/ja
Application granted granted Critical
Publication of JP4185366B2 publication Critical patent/JP4185366B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002589661A 2001-05-11 2002-05-10 抗原−特異的Ｔｒ１リンパ球を得る方法 Expired - Fee Related JP4185366B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
PCT/FR2002/001586 WO2002092793A1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Publications (3)

Publication Number Publication Date
JP2004526459A JP2004526459A (ja) 2004-09-02
JP2004526459A5 true JP2004526459A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4185366B2 JP4185366B2 (ja) 2008-11-26

Family

ID=8863160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589661A Expired - Fee Related JP4185366B2 (ja) 2001-05-11 2002-05-10 抗原−特異的Ｔｒ１リンパ球を得る方法

Country Status (10)

Country Link
US (2) US8076133B2 (cg-RX-API-DMAC7.html)
EP (1) EP1390474B1 (cg-RX-API-DMAC7.html)
JP (1) JP4185366B2 (cg-RX-API-DMAC7.html)
AT (1) ATE354641T1 (cg-RX-API-DMAC7.html)
CA (1) CA2446981C (cg-RX-API-DMAC7.html)
DE (1) DE60218302T2 (cg-RX-API-DMAC7.html)
DK (1) DK1390474T3 (cg-RX-API-DMAC7.html)
ES (1) ES2282425T3 (cg-RX-API-DMAC7.html)
FR (1) FR2824567B1 (cg-RX-API-DMAC7.html)
WO (1) WO2002092793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
AU3066599A (en) 1998-03-03 1999-10-18 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1463799A4 (en) * 2001-12-21 2006-01-18 Univ Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
FR2852967B1 (fr) * 2003-03-26 2007-12-07 Txcell Procede d'obtention de cellules dendritiques et de cellules t
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
AU2004288646A1 (en) * 2003-11-12 2005-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of lipopeptides for activating T lymphocytes through the skin
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CA2575689C (en) * 2004-08-11 2013-04-02 Txcell Tr1 cells for use in atherosclerosis
WO2006050138A2 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
SI1739166T1 (sl) * 2005-07-01 2011-11-30 Txcell S A PRIDOBIVANJE CELIC Tr1 SPECIFIČNIH ZA ALIMENTARNI ANTIGEN ALI AVTOGEN IZ LEVKOCITNE ALI PBMC POPULACIJE
CA2619735C (en) * 2005-08-31 2014-05-27 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
GB0603081D0 (en) * 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
US8124408B2 (en) * 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
KR20100063052A (ko) * 2007-08-02 2010-06-10 아이에스에스 이뮨 시스템 스티뮬레이션 에이비 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
JP5539886B2 (ja) 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
ES2393936T3 (es) 2008-04-28 2013-01-02 Txcell Composiciones para tratar una afección auto-inmune inflamatoria
EP2113560A1 (en) 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2221364A1 (en) * 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
EP2439534A1 (en) * 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
CA2831018A1 (en) 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2019237378A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将CD274基因定点整合至Jurkat细胞的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277635B1 (en) * 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
CA2245170A1 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
ATE347588T1 (de) * 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods

Similar Documents

Publication Publication Date Title
JP2004526459A5 (cg-RX-API-DMAC7.html)
Tang et al. Regulatory T-cell therapy in transplantation: moving to the clinic
EP1390474B1 (fr) Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US20230310562A1 (en) Antigen presenting scaffolds for immune-cell manipulation
Moser et al. γδ T-APCs: a novel tool for immunotherapy?
JP2006020648A5 (cg-RX-API-DMAC7.html)
Ureta et al. Generation of dendritic cells with regulatory properties
Northrop et al. CD8+ T-cell memory: only the good ones last
US20120114597A1 (en) Cd4+cd25- t cells and tr1-like regulatory t cells
JP2002539805A5 (cg-RX-API-DMAC7.html)
Fisher et al. T-regulatory cells for the treatment of autoimmune diseases
Milward et al. Enhancing human regulatory T cells in vitro for cell therapy applications
IL273698B1 (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
Freudenthal et al. Human blood dendritic cells
JP2002500872A5 (cg-RX-API-DMAC7.html)
Moberg An appreciation of Ralph Marvin Steinman (1943–2011)
Chen et al. Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival
Arthur et al. Dental pulp stem cells
Au et al. A strategy to purify, expand and gene-mark regulatory T cells (tregs) for use in the treatment of chronic Graft-Versus-Host Disease (GVHD)
EP1391504A1 (en) CD4+ CD25- T cells and Tr1-like regulatory T cells
Lim et al. A GD Type of Cancel Culture
Yingxi et al. Strategies for Generating Regulatory Dendritic Cells and the Clinical Application of Immune Tolerance.
LESHEM et al. Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture
Moreau et al. Semi-mature Bone Marrow Derived DC Expand Foxp3+ CD4+ CD25+ CD127-Regulatory T Cells with Suppressive Activity in the Macaque
Lord et al. Sa. 116. Loss of Regulatory T Cell Function Mediated by Antigen Presenting Cells from Surgically Resected Colons from IBD Patients